Gene expression patterns as well as gene interactions are under investigation for their involvement in tumour heterogeneity. The molecular classification of breast cancer based on hormone receptor expression, grade and HER2 receptor levels, is indicative but not adequate enough to complete the prognostic data. The objectives of this study were to ...

PURPOSE Recently, several prognostic gene expression signatures have been identified; however, their performance has never been evaluated according to the previously described molecular subtypes based on the estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2), and their biological meaning has remained unclear. Here we aimed to perform a comprehensive meta-analysis integra...

Objective: HEr2/neu is overexpressed/amplified in 20% of breast cancers. HEr2/neu status plays a role in determining the patients who might benefit from hormonal therapy and targeted therapy with Trastuzumab. The main cause of HEr2/neu overexpression is gene amplification. 10-25% of patients show Topoisomerase II-alpha gene alterations with HEr2/neu amplification. The objective of this study wa...

Purpose: To analyze HER2 status in primary breast cancer (BC) compared with correspondent metachronous metastases and to investigate whether BC phenotype may be predictive of change in HER2 expression. Experimental Design: HER2 was investigated by immunohistochemistry, silver (SISH) and fluorescent in situ hybridization (FISH), in a series of 137 tumors, building up a tissue microarray to concu...

Background: Human epidermal growth factor 2 (HER2) is known to be an important prognostic in breast cancer. Numerous studies have shown HER2+ cancers reduced overall survival and recovery time, as well the efficacy of anti-HER2 therapies along with chemotherapy improving disease outcomes. For this reason, it recommended that all patients cancer should evaluated for HER2 status. This study aimed...

PURPOSE Uterine serous carcinoma (USC) is an aggressive subtype of endometrial cancer that commonly harbors HER2 gene amplification. We investigated the effectiveness of HER2 inhibition using lapatinib and trastuzumab in vitro and in xenografts derived from USC cell lines and USC patient-derived xenografts. EXPERIMENTAL DESIGN Immunohistochemistry and FISH were performed to assess HER2 expres...

Gene amplification of HER2/ErbB2 occurs in gastric cancer and the therapeutic efficacy of the HER2-targeted antibody, trastuzumab, has recently been improved against HER2-positive advanced stomach cancer. Here, we examined whether Y-box-binding protein-1 (YB-1) could selectively control HER2 gene expression and cellular sensitivity to EGF receptor (EGFR) family protein-targeted drugs in human g...

AIMS The clinical significance of TOP2A as a prognostic marker has not been clarified. The aims of this study were to investigate the frequency of TOP2A copy number change; to correlate TOP2A with HER2 status, hormone receptor (HR) status and molecular subtype, and further to explore differences in breast cancer-specific survival according to TOP2A and HER2. METHODS In this study, TOP2A, HER2...

Purpose: Chemotherapy plus trastuzumab is standard of care for HER2-positive advanced gastric cancer (AGC). However, not all patients with HER2-positive AGC seem to benefit from trastuzumab. We evaluated the association between treatment outcomes with trastuzumab and HER2 status in patients with HER2positive AGC. Experimental Design: We enrolled 126 patients with HER2positive AGC treated with t...